PICO | Inclusion Criteria |
---|---|
Participants | • Persons with knee OA |
Interventions | • Intraarticular corticosteroids o Triamcinolone o Methylprednisolone o Betamethasone o Triamcinolone Sustained Release • Intraarticular Hyaluronic Acids • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) o Diclofenac o Celecoxib o Naproxen • Acetaminophen • Oral Opioids |
Comparators | • Any |
Outcomes | • Efficacy (pain hierarchy from highest to lowest priority) o WOMAC pain subscale (Likert; 0–20) (VAS; 0–500) o Pain during activity (VAS; 0–100) o Pain during walking (VAS; 0–100) o Global knee pain (VAS; 0–100) o Pain at rest (VAS; 0–100) o SF-36 (bodily pain (BP) subscale; 0–100) o HAQ (pain subscale; 0–100/0–3), Lequesne algofunctional index (pain subscale; 0–8), AIMS (pain subscale; 0–10), Knee-Specific Pain Scale (KSPS), McGill Pain Questionnaire (pain intensity; 0–50), ASES (pain subscale; 10–100), SES (Schmerzempfindungsskala – pain perception scale) o Pain at night (VAS; 0–100), pain during activity (NRS; 0–10), pain on walking (NRS; 0–10), number of painful days (days) |